Friday 14th November 2003 |
Text too small? |
Basically, Blis is moving away from investing in research and development and needs cash to focus on rolling out its products internationally.
The trouble is local sales were unimpressive over the past six months and getting a start in the US and Asia typically is expensive.
Blis chief executive Kelvin Moffatt said the issue size came down to a trade off between R&D and getting existing products to market.
"The amount of cash we are raising reflects that point."
In other words the directors realise it is time to start making money.
Moffatt expressed disappointment at the company's domestic performance during the winter, with operating revenue dipping 10% to $269,000 in the six months to September.
"We probably rested on our laurels a bit ... but the New Zealand market was never going to be the answer to our income we need to look internationally."
Blis has three products on the go, including its flagship K12 bacterial throat protector, a tooth decay preventative and a halitosis preventative.
The company was targeting Asia for sore throat treatment and the US for its oral hygiene products.
Blis shares received a boost in September following a deal to register and sell K12 in China but have since dropped back to below 30c.
No comments yet
MPG - Recapitalisation Closes Oversubscribed, Raises $23.9m
IPL - Indicative Issue Margin Range for Notes Offer
TWG partners with Tata Consultancy Services
Spark announces leadership team changes
September 15h Morning Report
Tower updates FY25 guidance
September 12h Morning Report
Scott Unveils Strategy and Delivers FY25 Trading Update
September 11h Morning Report
Devon Funds Morning Note - 10 September 2025